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Congenital heart disease (CHD) affects almost one percent of all live births. Despite
diagnostic and surgical reparative advances, the causes and mechanisms of CHD are
still primarily unknown. The extracellular matrix plays a large role in cell communication,
function, and differentiation, and therefore likely plays a role in disease development
and pathophysiology. Cell adhesion and gap junction proteins, such as integrins and
connexins, are also essential to cellular communication and behavior, and could interact
directly (integrins) or indirectly (connexins) with the extracellular matrix. In this work,
we explore disparities in the expression and spatial patterning of extracellular matrix,
adhesion, and gap junction proteins between wild type and Nkx2-5+/R52G mutant mice.
Decellularization and proteomic analysis, Western blotting, histology, immunostaining,
and mechanical assessment of embryonic and neonatal wild type and Nkx2-5 mutant
mouse hearts were performed. An increased abundance of collagen IV, fibronectin, and
integrin β-1 was found in Nkx2-5 mutant neonatal mouse hearts, as well as increased
expression of connexin 43 in embryonic mutant hearts. Furthermore, a ventricular
noncompaction phenotype was observed in both embryonic and neonatal mutant hearts,
as well as spatial disorganization of ECM proteins collagen IV and laminin in mutant
hearts. Characterizing such properties in a mutant mouse model provides valuable
information that can be applied to better understanding the mechanisms of congenital
heart disease.
Keywords: extracellular matrix, congenital heart disease, decellularization, proteomics, Nkx2-5, integrin, gap
junction, connexin
INTRODUCTION
Congenital heart disease (CHD) affects nine out of every 1,000 children born worldwide (1, 2),
or almost one percent of all live births. CHD is characterized by a variety of cardiac anomalies
(e.g., atrial or ventricular septal defect, patent ductus arteriosus, pulmonary valve stenosis), which
can affect blood flow through the heart as a result of holes between chambers or thickened
valves (3). While there have been many diagnostic and surgical advancements in detecting and
repairing cardiac defects in newborns or fetuses, the causes and mechanisms of these cardiac
maldevelopments are still primarily unknown and require further exploration.
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The Nkx2-5 transcription factor is one of the earliest
cardiogenic markers expressed during embryonic heart
development (4). Inherited mutations of the Nkx2-5 gene are a
common genetic cause of CHD in humans as they can result in
an assortment of cardiac malformations, such as right isomerism,
atrioventricular (AV) block, ventricular septal defect (VSD), and
atrial septal defect (ASD) (5–9). Over 50 Nkx2-5 mutations have
been identified that result in congenital heart defects, many of
which have been represented in mutant mouse models (6, 10–
12). We have previously developed a heterozygous knock-in
mutant mouse model with missense mutation 52Arg→Gly
(R52G) in the Nkx2-5 transcription factor homeodomain (13).
Mutant mouse hearts showed varying disease phenotypes among
samples, including Ebstein malformation and ventricular and
atrial septal defect, and all hearts demonstrated a ventricular
noncompaction phenotype. Ventricular noncompaction is a
condition in which the trabecular layer of the heart persists into
the ventricular walls, causing a spongy rather than compact
morphology and in turn limiting the heart’s ability to contract
and pump blood effectively (9, 14).
The extracellular matrix (ECM) and its remodeling
throughout development has been suggested to play a role
in ventricular compaction (15) as well as development of
other regions of the heart. For example, differential ECM
profiles exist throughout postnatal aortic valve maturation in
mice (16). Other research has shown some ECM irregularities
between diseased and healthy cardiac conditions (17, 18).
Increased production and disorganization of aortic valve cushion
ECM has been reported in a congenital aortic valve stenosis
mouse model (19). Additionally, irregular quantities of ECM
components such as hyaluronan may lead to altered cellular
behavior and downstream congenital heart defects (20). It is
currently unknown whether there is a relationship between
the Nkx2-5 genetic mutation, cardiac ECM, and subsequent
heart development. However, matrix composition and stiffness
have been suggested to alter embryonic development (21, 22).
Furthermore, as the ECM is integral to cell communication,
function, and differentiation (23), it could likely play a role in
disease development and pathophysiology.
Integrins and gap junction proteins also play a large role
in cardiac development, during which they possess dynamic
spatiotemporal profiles (17, 24–27). Integrins are transmembrane
proteins that mediate cell-matrix interactions by serving on
the cell surface as receptors for ECM ligands while connecting
to the cytoskeleton and various signaling cascades on the cell
interior (25). Modifications of adhesion-related proteins may
cause ECM irregularities. For example, removal of integrin-
linked-kinase, a protein that binds to beta integrins at focal
adhesion complexes, from the neural crest of murine hearts
resulted in outflow tract malformations and ventricular septal
defects, as well as reduced expression of ECM proteins (28).
Cardiac gap junction proteins, such as connexins, allow for
ion and small molecule transfer, which is essential for electrical
conduction and muscle contraction in the heart (27). Research
has suggested some connection between connexin 43 mutations
and cardiac malformations (27), and interestingly, between
Nkx2-5 mutations and connexin expression (29). However, it
is likely that connexins are not solely the cause of cardiac
malformations, and that a more complex cascade of cell-cell
and cell-ECM interactions play a role in such development
(27). Regardless, there is enough evidence to elicit further
exploration into the presence of gap junction protein and integrin
irregularities in congenital heart disease.
In this work, we explore disparities in the expression
and spatial patterning of extracellular matrix, adhesion, and
gap junction proteins between wild type and Nkx2-5+/R52G
mutant mice. Awareness of such trends allows us to better
understand how key ECM, integrin, and gap junction proteins
are differentially expressed in diseased hearts, and elicits further
research into their roles in the mechanisms of congenital heart
disease development and pathophysiology.
MATERIALS AND METHODS
Animal Models and Tissue Harvest
All animal experiments were performed with approval from the
Institutional Animal Care and Use Committee at the University
of Florida. 129/SvPasCrl mice were utilized in these studies
(Charles River Laboratories, Wilmington, MA) for wild type
samples. A subset of the mice were backcrossed with mutant
Nkx2-5+/R52G knock-in mice [described previously (13)] for at
least 10 generations. Nkx2-5+/R52G male mice were bred with
female wild type mice. To determine embryonic staging, mice
were plug-checked daily; the morning the vaginal plug was
found was considered embryonic day 0.5 (E0.5). On day E13.5,
mothers were sacrificed, and embryonic hearts were dissected
for histological analysis or Western blotting. Hearts were also
harvested from postnatal day 1 (P1) mice on the day of delivery.
Decellularization Process
A diffusion method of chemical decellularization, adapted
from previously published methods (30, 31), was employed.
Embryonic hearts were placed in 2mL low retention tubes (Fisher
Scientific 02-681-321), submerged with detergent and/or buffer,
and placed on a rotator at 15 rpm (Thermo Fisher) for the
following durations. Hearts were washed with ddH2O for 8 h,
sulfobetaine-10 (SB-10, Sigma Aldrich D4266) for 4 h, 100mM
Na/50mM phosphate-buffered saline (PBS) for 15min, 5%
sodium deoxycholate (SD, Sigma Aldrich D6750)/sulfobetaine-
16 (SB-16, SigmaAldrichH6883) for 4 h, 100mMNa/50mMPBS
for three 15-min periods, SB-10 for 1.75 h, 100mM Na/50mM
PBS for 15min, 5% SD/SB-16 for 3 h, 50mM Na/10mM PBS
for two 15-min periods, deoxyribonuclease I (DNase I, Sigma-
Aldrich D4527) solution for 12 h (with no rotation), and 50mM
Na/10mM PBS for 15min. Decellularized hearts, in fresh 50mM
Na/10mM PBS solution, were stored at−80◦C until further use.
Mass Spectrometry and Proteomic
Analysis
A detailed methodology can be found in the
Supplementary Material. Briefly, each E13.5 embryonic mouse
heart was submerged in 25 µL RIPA buffer (Millipore Sigma
20-188) containing HaltTM protease and phosphatase inhibitor
cocktail (Thermo Scientific Pi78444) and phenylmethylsulfonyl
Frontiers in Cardiovascular Medicine | www.frontiersin.org 2 May 2020 | Volume 7 | Article 93
Bousalis et al. Extracellular Matrix Disparities in CHD
fluoride (PMSF, Sigma Aldrich 10837091001) and sonicated
to homogenize into a lysate. To accurately compare between
unprocessed and decellularized hearts, and to account for
mass and intracellular protein loss during the decellularization
process, samples were normalized per whole heart. Lysate
samples were submitted to the UF Mass Spectrometry Research
and Education Center for processing and analysis. Scaffold
(version 4.9.0, Proteome Software Inc., Portland, OR) was used
to validate MS/MS based peptide and protein identifications.
Peptide identifications were accepted if they could be established
at >95.0% probability by the Peptide Prophet algorithm (32)
with Scaffold delta-mass correction. Protein identifications were
accepted if they could be established at >99.0% probability and
contained at least one identified peptide. Protein probabilities
were assigned by the Protein Prophet algorithm (33).
Western Blotting
For both embryonic and neonatal hearts, each heart was
immersed in RIPA lysis buffer, as described above, and sonicated
to homogenize the sample. After a 15-min incubation on ice,
tissue lysates were centrifuged to pellet any insoluble material.
Supernatants were collected and total protein content was
measured using a Pierce 660 Protein Assay (Thermo Fisher
Scientific 22660). For neonatal hearts, SDS-PAGE was performed
on samples, and proteins were transferred to 0.22µm PVDF
membranes (Bio-Rad Immun-Blot 1620177). Membranes were
blocked in Odyssey Blocking Buffer (LI-COR 927-50000) for
an hour, incubated in primary antibody solution overnight at
4◦C, washed in tris-buffered saline-Tween 20 solution (TBS-
T), incubated in secondary antibody solution for 2 h at room
temperature, washed, and imaged using a LICOR Odyssey CL-X.
Primary antibodies were diluted in Odyssey Blocking Buffer with
0.2% Tween 20 (Fisher Bioreagents BP337-100) at the following
ratios: fibronectin (Abcam ab2413) 1:500, laminin (Sigma L9393)
1:500, collagen IV (Sigma 4200500) 1:500, GAPDH (Abcam
ab8245) 1:2000. Secondary antibodies were either goat anti-rabbit
IgG IRDye 680RD (LI-COR 926-68071) or goat anti-mouse IgG
IRDye 800CW (LI-COR 926-32210) diluted 1:10,000 in Odyssey
Blocking Buffer with 0.01% SDS (Bio-Rad 1610301) and 0.2%
Tween 20.
Because of the small size and limited sample quantity available
from embryonic hearts, a ProteinSimple Wes capillary-based
system (Biotechne) was used in lieu of traditional Western
blotting, as it requires less total protein per assay (34). The
Wes system was also used for experiments in which target
proteins were generally of lower abundance to enhance signal
detection (for example, integrin β-1). Samples were prepped
according to ProteinSimple Wes recommended protocols. For
detection of laminin, collagen IV, fibronectin, integrin β-1,
integrin α-5, and lamin B1, samples were run on a 66-440 kDa
Jess/Wess separation module (ProteinSimple, Biotechne, USA
SM-W008). For detection of connexin 43 and GAPDH, samples
were run on a 12-230 kDa separation module (ProteinSimple,
Biotechne, USA SM-W004). Primary antibody dilutions and
sample concentrations are as follows: laminin 1:100, 0.25 µg/µL
sample loaded; collagen IV (Abcam ab6586) 1:100, 1.15 µg/µL
sample loaded; fibronectin 1:100, 0.005 µg/µL sample loaded;
lamin B1 (Cell Signaling Technologies 13435S) 1:100, 1.15µg/µL
sample loaded; GAPDH 1:100, 0.9µg/µL sample loaded; integrin
β-1 (Novus NBP2-16974), 1:100, 1.45 µg/µL for embryonic,
1.8 µg/µL for neonatal loaded; Connexin 43 (Cell Signaling
Technologies 3512S) 1:100, 0.45 µg/µL sample loaded; integrin
α-5 (Cell Signaling Technologies 4705T) 1:100, 0.2 µg/µL
sample loaded.
For traditional Western blotting analysis, LICOR Image
Studio Lite software was used to detect band intensities.
For capillary-based Westerns, chemiluminescence intensity
electropherograms were plotted and analyzed using
ProteinSimple’s Compass SW software. The area under
each curve peak corresponding to the protein’s molecular
weight was recorded for every sample, and these values were
used for statistical comparisons. A standardized exposure
time and peak fitting size was used for all of the samples per
target protein. For collagen IV Western blot quantification, the
prominent bands at 250 kDa and directly below were measured
for both traditional and capillary Westerns. Depending on the
target protein molecular weight, either lamin B1 or GAPDH
was used as a housekeeping protein for normalization (35).
To ensure the housekeeping protein expressions did not
significantly differ between mutant and wild type hearts, a
traditional Western blotting experiment was performed with
neonatal heart samples in which membranes were stained
for total protein with Ponceau S (Sigma-Aldrich P7170) after
transfer, and then probed for both GAPDH (1:2000 dilution)
and Lamin B1 (1:500 dilution). GAPDH and Lamin band
intensities were quantified and normalized to total protein band
intensities (Supplementary Figure 4). No significant differences
between neonatal wild type and mutant hearts were detected,
hence validating our use of these housekeeping proteins for
normalization of target proteins of interest.
Immunohistochemistry and Other
Histological Assessments
Hearts were fixed in 4% paraformaldehyde, soaked in sucrose
solution overnight, embedded in OCT Tissue-Tek (Electron
Microscopy Sciences 62550-12), and placed at 4◦C overnight.
Hearts were all placed in the same orientation immediately
prior to freezing at −80◦C, and cryosectioned into 10-µm
sections parallel to the coronal plane, along the sagittal plane,
using a Leica CM 1950 Cryostat. Sections in which all four
chambers of the heart were visible were used for immunostaining
and histological assessment. Slides were warmed at 37◦C for
2 h, incubated with blocking buffer [3% goat serum, (Sigma
G9023), 0.3% Triton X-100 (Sigma 93443) in 1X PBS] for an
hour, incubated in primary antibody solution overnight, then
secondary antibody solution overnight, and then DAPI for
10min, with 1X PBS washes in between each incubation step.
Primary antibody solutions consisted of collagen IV (Abcam
ab6586) and laminin at 1:200 dilutions in blocking buffer.
Secondary antibody solution consisted of goat anti-mouse IgG
Alexa Fluor 488 (Thermo Fisher A-11001), goat anti-rabbit IgG
Alexa Fluor 647 (Abcam ab150079), or goat anti-mouse IgG
Alexa Fluor 568 (Thermo Fisher A-11011) at 1:500 dilution
Frontiers in Cardiovascular Medicine | www.frontiersin.org 3 May 2020 | Volume 7 | Article 93
Bousalis et al. Extracellular Matrix Disparities in CHD
FIGURE 1 | Decellularization creates ECM-rich hearts for proteomic assessment. (A) Top: Image of the same embryonic heart before and after decellularization.
Middle: DAPI staining demonstrating removal of nuclear materials from tissue post-decellularization. Bottom: Immunostaining demonstrating preservation of laminin
throughout the decellularization process. DAPI and Laminin scale bars: 20µm. Images shown are representative of three biological replicates. Laminin staining used
Alexa Fluor 647 dye but was pseudo-colored yellow for ease of comparison across graphics. (B) Heat map displaying ECM proteins detected in mass spectrometry
analysis with at least one average spectral count per group. Color is based on the average spectral count value of three biological replicates.
in blocking buffer. Coverslips (1.5mm, Erie Scientific) were
mounted on each slide using Fluoromount-G slide mounting
medium (Thermo Fisher OB100-01) and left to dry overnight.
Slides were imaged using a Zeiss Axioimager Z2 or a Zeiss 880
Confocal Laser Scanning Microscope.
Neonatal laminin immunohistochemical images were semi-
quantified using ImageJ software. Three to five rectangular
regions of interest (ROIs), all of the same size (15,000 µm2),
were assigned in each section. Regions were placed along the
ventricular walls because this is where the ventricular non-
compaction phenotype of interest persists. Then, all the enclosed
pores present in the staining were traced in each region of
interest. Please refer to Supplementary Figure 2 for a visual
example of analysis. Authors were blinded to the identification of
the ROIs during pore tracing. The area and circularity values were
obtained for each of the pores traced. Additionally, an ellipse was
fit to each pore, and its central angle relative to the horizontal
axis was recorded. These data were averaged for each ROI, which
were then averaged per heart sample. To obtain angle deviation
calculations, the standard deviation values per ROI were obtained
for the central angles of fitted ellipses. The average “deviation”
value was used as a metric for pore alignment.
For hematoxylin and eosin staining, embryonic hearts were
fixed, embedded in paraffin, and sectioned into 5µm sections
using a microtome. Neonatal hearts were processed as described
above and cryosectioned. Slides with paraffin sections were
deparaffinized and underwent a sequence of rehydration in
aqueous ethanol solutions. Cryosections were fixed in 80%
methanol and incubated in PBS to remove OCT. Both types
of sections underwent washes in Harris hematoxylin (Sigma-
Aldrich HHS16), water, bluing solution (Leica 3802915), water,
defining solution (Leica 3803590), 80% ethanol, eosin Y (Electron
Microscopy Sciences 26051-10), 95 and 100% ethanol, and
xylenes (Avantor 8668-16).
Statistical Analysis
Power analyses were performed using JMP Pro software to
determine the sample sizes required to ensure that claims of
statistical significance were sufficiently powered (80 percent or
higher). The only experiment not sufficiently powered is the
neonatal fibronectin Western blot (n = 3 per group) because
we were unable to obtain a sufficient number of samples for
extraneous reasons. All experiments were performed with at least
n = 3 biological replicates (i.e., individual hearts) per group,
and the exact number is specified in each figure caption. When
comparing between two groups, a student’s t-test was performed
using GraphPad Prism and significance was considered a two-
tailed p ≤ 0.05. If data from the two groups possessed unequal
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FIGURE 2 | Western blotting detects significant differences in collagen IV and fibronectin at the neonatal age, but no differences in ECM expression between
embryonic Nkx2-5 mutant and wild type mouse hearts. For embryonic heart samples: ECM capillary-based Western band images for embryonic heart samples (left)
and subsequent quantification (right) for laminin (A), collagen IV (B), and fibronectin (C). Each lane displays a representative “pseudoblot” band for each group, with n
= 5 for each group. Each target ECM protein band intensity was normalized to that sample’s lamin B1 intensity. For neonatal heart samples: traditional Western
blotting representative bands (left) of (D) laminin (n = 12 total), (E) collagen IV (n = 12 total), and (F) fibronectin (n = 6 total) and corresponding quantifications (right).
Control (“Ctrl”) lane shows each respective purified protein probed with the same primary antibody as the samples. Each target ECM protein band intensity was
normalized to that sample’s GAPDH intensity. Graphs display mean ± standard deviation of ECM band intensities normalized to housekeeping protein, relative to wild
type group. Significance *p < 0.05. W, wild type; M, mutant.
variances, a t-test with Welch’s correction was performed using
GraphPad Prism and significance was considered a two-tailed p≤
0.05. For proteomic analysis, significance threshold is described
in the appropriate section that accounts for false detection from
multiple comparisons.
RESULTS
Decellularization Creates ECM-Rich Hearts
for Proteomic Assessment
An initial proteomic assessment was performed on E13.5
embryonic wild type and Nkx2-5 mutant mice as a discovery
method to identify proteins of interest that differed between the
two groups. As ECM proteins were of greatest interest in this
study, hearts were decellularized to remove intracellular
content and to generate ECM-rich hearts. Analysis of
decellularized tissue, rather than unprocessed tissue, allows
for better proteomic detection of ECM proteins, since highly
abundant cellular proteins (e.g., myosin, actin) can mask the
signal of generally lesser-abundant ECM proteins (36, 37).
Embryonic hearts underwent a novel method of diffusion-
based decellularization [adapted from Hudson et al. (30)
and McCrary et al. (31)] utilizing anionic detergent sodium
deoxycholate, zwitterionic detergents sulfobetaine-10 and−16,
and enzyme deoxyribonuclease (DNase). Immunostaining
was used to confirm removal of intracellular content and
preservation of extracellular matrix proteins. Figure 1A
shows that the heart shrinks and loses its initial pinkish hue
after decellularization, demonstrating the loss of cellular
content. Additionally, no DAPI staining was detected in
decellularized tissue, implying that no nuclear content remained
after processing. Finally, laminin immunostaining revealed
comparable staining intensities between unprocessed and
decellularized tissue. After these preliminary assessments
confirmed intracellular content removal and preservation
of extracellular matrix proteins, decellularized hearts were
homogenized, and submitted for mass spectrometry and
proteomic analysis.
Through mass spectrometry, 1,324 total proteins were
detected, with 35 being ECM or ECM-related proteins.
Figure 1B displays the relative abundance of common ECM and
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ECM-related proteins, which had at least one average spectral
count (out of biological triplicates) detected. The full table of
detected proteins with at least one average spectral count is
provided in Supplementary Table 1, with the p-values of each
comparison. The majority of detected ECM proteins appeared
to be more abundant in mutant tissue, with the exception of
desmoplakin, fibrillin-1, nidogen-1 and - 2, and collagen IV
alpha 2 chain. The proteomic data were used primarily as a
preliminary “discovery” method to identify proteins of interest,
which were further validated with other quantitative and semi-
quantitative methods. As most laminins and collagens, as well as
fibronectin, were more abundant in mutant hearts according to
these data, we focused on laminin, collagen IV, and fibronectin
for further assessments.
Compositional ECM Differences in Wild
Type and Nkx2-5 Mutant Hearts
To further explore differential expression of ECM proteins of
interest (based on preliminary proteomics results), Western
blotting was performed on E13.5 wild type and mutant
hearts for laminin (all subunits), collagen IV (all subunits),
and fibronectin (all subtypes). Due to the small size of
embryonic heart samples, an automated capillary-based Western
blotting method was used to preserve protein and sample.
Chemiluminescence intensity profiles of each protein were
plotted and analyzed (Figures 2A–C). Expression of laminin,
collagen IV, and fibronectin did not significantly differ between
groups. Samples were all probed for housekeeping protein lamin
B1 in addition to proteins of interest. During analysis, the
ECM protein band intensities were normalized to each sample’s
respective lamin B1 band intensity to account for any sample
prep and/or loading variations.
Western blotting was also performed on neonatal
(postnatal day 1, P1) wild type and mutant mouse hearts to
demonstrate whether trends in ECM differences vary temporally
(Figures 2D–F). Trends remained consistent for laminin,
where no difference was detected between mutant and wild
type samples. Collagen IV, although not significantly different
at the embryonic stage, showed a statistically significant 25
percent increase in neonatal mutant hearts compared to neonatal
wild type hearts. Furthermore, fibronectin was expressed 71
percent more in neonatal mutant hearts than wild type hearts.
Housekeeping protein GAPDH was used for normalization.
Gross Morphological Differences and
Visualization of ECM Distribution and
Patterning
It has been previously published that postnatal Nkx2-5 mutant
mouse hearts possess hypertrabeculations due to ventricular
noncompaction phenotype (13). Figure 3A demonstrates
that such phenotype is apparent in embryonic as well as
neonatal mutant hearts (Figure 3B). It was assumed that
mutant hearts may possess different mechanical properties
than their wild type counterparts because of this noncompact,
spongy morphology. Neonatal heart mechanical properties
were determined using indentation. No significant differences
in mechanical properties were detected between wild type and
mutant hearts. More information and results can be found in
Supplementary Figure 1.
Immunostaining was performed on embryonic and neonatal
wild type and Nkx2-5 mutant hearts for laminin and collagen
IV to assess any spatial or organizational pattern differences.
Particular attention was given to the ventricular wall regions of
the hearts, where Nkx2-5 mutant mice possess the ventricular
noncompaction phenotype (13). Since trabeculations are known
to persist in mutant hearts compared to wild type hearts,
these areas of interest were viewed at higher magnifications.
Laminin does not appear to differ greatly between wild type
and mutant embryonic hearts, while differences are apparent at
the neonatal age (Figure 4A), where the laminin forms shorter,
more diffuse networks in mutant neonatal hearts compared to
their wild type counterpart. Further, collagen IV appears to be
less spatially organized in mutant hearts of the neonatal age
compared to wild type hearts (Supplementary Figure 2A). To
quantitatively assess such disorganization, the area, circularity,
and alignment of pores visualized by laminin staining along
the ventricular walls of wild type and Nkx2-5 mutant hearts
were measured. Mutant hearts had a significantly greater
number of pores per given area (Figure 4B) and the average
pore size of mutant hearts was less than three times that
of wild type hearts (Figure 4C). Additionally, mutant laminin
pores had a significantly greater circularity value (on a scale
of 0–1, where a value of 1 represents a perfect circle)
(Figure 4D). The smaller, more abundant round pores are
indicative of less organization of the ECM compared to the
fewer elongated and larger pores apparent in the wild type
hearts. Additionally, although it appears from some images that
wild type laminin pores are also more uniformly aligned in a
given direction, when quantifying how much the pore angles
in each region of interest deviate from each other, we did
not see any significant differences between the two genotypes
(Supplementary Figure 2C).
Adhesion and Gap Junction Protein
Expression
Results demonstrating differential abundance of collagen IV
and fibronectin in wild type and Nkx2-5 mutant neonatal
hearts motivated interest to explore expression of cell adhesion
molecule integrin β-1, which binds to both of these ECM
proteins, and integrin α-5, which dimerizes with integrin
β-1 to serve as a fibronectin receptor. Connexin 43 (also
known as gap junction protein alpha-1), although not directly
in contact with the ECM, also plays an essential role in
cardiac cell communication, conduction, and contraction
(38). Western blotting of these proteins demonstrated a
52 percent statistically significant increase in connexin 43
expression in mutant hearts compared to wild type hearts
at the embryonic age (Figures 5B,D). This trend does not
persist in neonatal mice, where there are no differences
in connexin 43 expression between the two genotypes.
Integrin β-1, however, possesses the opposite trend, where
no differences are detected between mutant and wild type
Frontiers in Cardiovascular Medicine | www.frontiersin.org 6 May 2020 | Volume 7 | Article 93
Bousalis et al. Extracellular Matrix Disparities in CHD
FIGURE 3 | Hematoxylin and eosin staining demonstrates ventricular noncompaction phenotype at both embryonic and neonatal ages in mutant Nkx2-5 mouse
hearts (A) Embryonic heart and (B) neonatal heart hematoxylin and eosin staining demonstrating the ventricular noncompaction phenotype characteristic of mutant
hearts. OFT, outflow tract; RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; *VSD, ventricular septal defect.
embryonic hearts, however a 93 percent statistically significant
increase in expression is seen in mutant neonatal mouse hearts
(Figures 5A,C). Western blotting for integrin α-5 expression
in neonatal wild type and Nkx2-5 mutant hearts did not
reveal any significant differences between the two genotypes
(Supplementary Figure 3).
DISCUSSION
One focus of this study was to characterize disparities in the
ECM of wild type and Nkx2-5 mutant mouse hearts. Although
this study was not a comprehensive investigation into all
potential ECM disparities that may exist, we chose three key
ECM proteins, collagen IV, laminin, and fibronectin, to explore
based on discovery mass spectrometry data. Two different
ages were assessed (embryonic and neonatal), which provided
insight into potential ECM dynamics throughout disease
development. For target proteins, no significant differences in
ECM expression were found until the neonatal age, at which
point mutant hearts showed increased expression of collagen
IV and fibronectin. Collagen IV is a major component of the
basement membrane, which is essential for maintaining tissue
structure and regulating cardiac contractility (39). Fibronectin
is a structural glycoprotein that can influence cell behavior
through its contact with both the basement membrane, fibrillar
collagen network, and integrin receptors (40, 41). Fibronectin-
integrin interactions can lead to downstream signaling cascades
that control cytoskeleton reorganization and cell spreading,
migration, and proliferation (40); thus, it is likely that ECM
irregularities have some indirect link to cardiac malformations,
such as the ventricular noncompaction phenotype seen in
these studies.
Hematoxylin and eosin staining demonstrated that similar
phenotypes exist in both embryonic and neonatal Nkx2-5
mutant hearts. Although it has previously been demonstrated
that neonatal mutant hearts possess ventricular noncompaction
phenotypes (13), it has not been shown before that this
phenotype takes form at or before the E13.5 stage. This is
feasible, as trabeculation is thought to begin at embryonic
day 9–9.5 in mice (42). Furthermore, our histology and ECM
immunostaining data agree with previous research on ventricular
noncompaction (15), with greater disorganization present in
the compact and trabecular layers of the heart. Interestingly,
although laminin was not differentially abundant between the
two genotypes, immunostaining quantification demonstrated
less spatial organization of laminin in neonatal Nkx2-5 mutant
hearts. This indicates that ECM spatial arrangements can
differ despite no change in overall abundance of the ECM
protein. While other groups have explored the mechanisms
of Notch and Nrg1 signaling in trabeculation (15), there
is little existing research regarding the effect of Nkx2-5
mutations on trabeculation during cardiac development. Here,
we have shown that there is some connection between
the two.
Assessments of adhesion proteins (integrin β-1 and α-5)
and a gap junction protein (connexin 43) were also performed
through Western blotting to obtain insight on upstream or
downstream effects of ECM irregularities. Integrin β-1 was
significantly overexpressed in neonatal mutant mouse hearts,
whereas no significant differences were detected at the embryonic
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FIGURE 4 | Laminin immunostaining reveals organizational differences between wild type and Nkx2-5 mutant ECM. (A) Laminin (yellow) immunostaining on both
embryonic and neonatal wild type and Nkx2-5 mutant mouse hearts. Embryonic scale bars: 100µm. Neonatal scale bars: 200µm. Laminin staining used Alexa Fluor
647 dye but was pseudo-colored yellow for ease of comparison across graphics. (B) Average number of pores measured per 15,000 µm2 area of tissue. (C) Measure
of average pore size in µm2 across neonatal wild type and mutant laminin staining. (D) Measure of average circularity of neonatal pores, where a circularity of “1” is a
perfect circle. For quantification, n = 6 for wild type and n = 5 for mutant hearts. Graphs show mean ± standard deviation with significance *p < 0.05, **p < 0.01,
and ***p < 0.001.
age. Integrin β-1 can form a dimer with α integrins 1-8, 10-11,
and v to serve as ligands for laminin, collagen, and fibronectin
(24, 43); therefore, it is fitting that these data correspond
to the significant increase in collagen IV and fibronectin in
neonatal mutant mouse hearts. Although integrin β-1 expression
was increased in mutant hearts, no significant differences in
expression of integrin α-5 were found between genotypes. This
differential expression may be due to the specific functional
roles that β-1 and α-5 have in cardiac development and
myocyte function (44, 45). Integrin β-1 is known to form
at least 12 different heterodimers with various α integrins,
whereas integrin α-5 only binds to β-1 (43). Furthermore,
there are multiple other integrin heterodimers that serve as
fibronectin receptors, including αvβ1, α4β1, and α9β1 (43,
46), thus it cannot be assumed that increased abundance of
fibronectin would linearly correlate specifically to abundance of
integrin α-5.
On the contrary, connexin 43 was significantly increased
in embryonic mutant mouse hearts, with no trends apparent
at the neonatal stage. Interestingly, connexin 43 is primarily
present in trabeculated areas of the ventricle during embryonic
development until around E15.5, after which point it becomes
present throughout the entirety of the ventricular walls
(47, 48). Overexpression of connexin 43 can also lead to
heart defects such as right ventricle enlargement and non-
compaction, trabecular disorganization, conotruncal region
enlargement, and outflow tract abnormalities (49). Although
the findings of Coppen et al. (48) and Ewart et al. (49) were
not related to Nkx2-5 mutations, they align with the ventricular
noncompaction phenotype present in our E13.5 Nkx2-5
mutant mouse heart samples. Furthermore, as connexin 43
holds major roles in cell signaling, mechanotransduction,
ion exchange, and conduction (47, 50), its differential
abundance in embryonic hearts potentially has both direct
and indirect effects on development. Hence, there are
likely indirect relationships between increased connexin 43
expression and downstream ECM production that require
further exploration.
It should be noted that some limitations to the assessments
performed in this study exist. For example, although
tandem mass spectrometry is a powerful tool for proteome
characterization, its analysis is restricted to proteins solubilized
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FIGURE 5 | Western blotting demonstrates increased integrin β-1 and connexin 43 expression in neonatal and embryonic mutant Nkx2-5 hearts, respectively.
Capillary-based Western botting images and corresponding quantifications of embryonic wild type and mutant (A) integrin β-1 and (B) connexin 43 (Cx43), and
neonatal wild type and mutant (C) integrin β-1 and (D) connexin 43. Graphs display mean ± standard deviation of protein band intensities normalized to either lamin
B1 or GAPDH housekeeping proteins. Significance **p < 0.01. n = 8 total for embryonic and 9 total for neonatal integrin β-1 Westerns. n = 10 total for embryonic and
9 total for neonatal connexin 43 Westerns.
during tissue homogenization (51). As some ECM proteins are
difficult to solubilize, it is possible that some proteins were lost
in the sample preparation process. This could be attributed to
why other common types of collagen, such as type 1 collagen,
were not detected in this study. For this reason, proteomic
analysis was used as a qualitative discovery tool, and proteins
of interest were selected for further investigation with other
methods. Regardless, Western blotting results were aligned
with proteomic data, which suggested increased amounts of
collagens, laminin, and fibronectin in mutant hearts. Although
mass spectrometry data for embryonic hearts aligned more
with the neonatal rather than embryonic Westerns, there
were no contradicting proteomic and Western blotting data—
either no significant differences were detected, or there was
significantly increased ECM expression in mutant hearts.
This could be attributed to sensitivity differences of the two
techniques. Furthermore, perhaps ECM deposition increased
over the course of development as a mechanism to provide
cells with structural support to counteract the noncompaction
phenotype sponginess, at which point the ECM amount and
expression difference could be large enough for detection
through Western blotting.
While we have investigated three select ECM proteins,
there is a need for a more thorough investigation into other
potential ECM differences, particularly in fibrillar collagen
and lesser abundant ECM proteins not detected in this
study. In the future, recently developed ECM solubilization
techniques (51, 52), quantitative mass spectrometry methods
(53, 54), and targeted mass spectrometry (55) could be
applied to obtain more precise details about the ECM
composition of wild type and mutant hearts. Additionally,
other target proteins could be selected from our preliminary
mass spectrometry assessment for further exploration via
Western blotting. For example, desmoplakin was not detected
in mutant mouse hearts at all, whereas it was present
in wild type hearts, and it has also been associated with
cardiomyopathies (56).
In summary, we report interesting trends in collagen
IV, laminin, fibronectin, and ECM-related proteins of wild
type and Nkx2-5 mutant mouse hearts. This study provides
information regarding morphological differences, mechanical
properties, ECM spatial distribution, and relative abundance
of ECM, connexin, and adhesion proteins in wild type and
mutant hearts. One possible application for characterizing
such properties in a mouse model would be replicating these
parameters in 3D hydrogel ECM-based tissue mimics that
serve as scaffolds for healthy and diseased cells. Applying
different stimuli or screening therapeutic strategies could allow
for greater mechanistic insight of congenital cardiac anomalies.
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